Form 4: Vaxcyte Director Heath Lukatch Reports Acquisition of Stock Options and Restricted Stock Units

Director Heath Lukatch reports acquisition of stock options and restricted stock units in Vaxcyte, Inc.

Summary

• On June 6, 2024, Heath Lukatch, a director of Vaxcyte, Inc. (PCVX), reported the acquisition of 1,550 shares of Common Stock underlying restricted stock units (RSUs) at a price of $0.
• These RSUs will fully vest on the earlier of June 6, 2025, or the day prior to the next annual meeting of stockholders, subject to acceleration and continuous service.
• Lukatch also acquired options to purchase 7,250 shares of Common Stock at an exercise price of $72.51.
• These options vest monthly and will fully vest on the earlier of June 6, 2025, or the day prior to the next annual meeting of stockholders, subject to acceleration and continuous service.
• Following these transactions, Lukatch beneficially owns 7,175 shares of Common Stock and options to purchase 7,250 shares of Common Stock.
• A Power of Attorney was executed on June 7, 2024, granting certain individuals the authority to execute and file Forms 3, 4, and 5 on behalf of Heath Lukatch.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine transaction.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future performance.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates